CLINICAL_TRIALS
trial_result
· 2018-07-10
Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention [Phase 2]
Summary
Phase 2 trial update on Erenumab (AMG 334) for migraine prevention completed with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Migraine | Phase 2 | Status: COMPLETED | Results posted: 2018-07-10